Joel Schwartz, DMD, DMedSc
Oral Medicine and Diagnostic Sciences
Building & Room:
801 S. Paulina Street, IL 60612
Schwartz JL, Brunnemann KD, Adami AJ, Panda S, Gordon SC, Hoffmann D, Adami GR. Brand specific responses to smokeless tobacco in a rat lip canal model. J Oral Pathol Med. 2010 Jul;39(6):453-9.
Ye H, Yu T, Temam S, Ziober BL, Wang J, Schwartz JL, Mao L, Wong DT, Zhou X. 2008. Transcriptomic Dissection of Tongue Squamous Cell Carcinoma. BMC Genomics. In Press.
Schwartz JL, Panda S, Beam C, Bach LE, Adami GR. 2007. RNA from brush oral cytology to measure squamous cell carcinoma gene expression. J Oral Pathol Med (in press).
Wilder-Smith P, Hammer-Wilson MJ, Zhang J, Wang Q, Osann K, Chen Z, Wigdor H, Schwartz JL, Epstein J. 2007. In vivo imaging of oral mucositis in an animal model using optical coherence tomography and optical Doppler tomography. Clin Cancer Res 13(8):2449-54.
Schwartz JL, Baker V, Larios E, Chung FL. 2005. Molecular and cellular effects of green tea on oral cells of smokers: a pilot study. Mol Nutr Food Res 49(1):43-51.
Schwartz JL, Baker V, Larios E, Desai D, Amin S. 2004. Inhibition of experimental tobacco carcinogen induced head and neck carcinogens. Oral Oncology 40: 611-623.
Research Currently in Progress
Dr. Schwartz develops various oral cancer models to understand and quantify the earliest genetic and molecular events that change a normal cell to a cancer cell following exposure to virus or chemical carcinogen. First, in laboratory models Dr. Schwartz studies viral and chemical oral carcinogenesis using normal, transformed premalignant and malignant cells. Second, in animals such as, hamster, rat, and mouse, he validates laboratory findings and further assesses genetic and molecular progression as he changes a normal cell to a cancer cell. His approach also involves non-invasive screening of this process using oral cytology samples and RNA microarray. This method is unique because he harvests from the identical animal samples throughout the process of oral carcinogenesis. An identical approach is translated to clinical human populations to validate findings, to study early prevention or to monitor various therapies to improve the quality of life for the oral cancer patient.